Tenofovir: FDA approved for treatment of hepatitis B
The nucleotide analogue tenofovir has received FDA approval for treatment of hepatitis B virus (HBV) infection. Approval was based on studies of HIV-uninfected patients, but limited data have demonstrated the efficacy of tenofovir for HIV/HBV-coinfected patients, and in recent years tenofovir commonly has been used in ARV regimens to treat both HIV and hepatitis B for coinfected patients.
Current DHHS adult treatment guidelines and NIH/CDC/HIVMA/IDSA opportunistic infection treatment guidelines recommend that HIV/HBV-coinfected patients who are treated for HIV should be treated simultaneously for HBV, with tenofovir as one option for treating both infections. To avoid the development of HIV-associated resistance, tenofovir should be used only as part of an ARV regimen that will fully suppress HIV viremia.
The recommended tenofovir dosage for the treatment of chronic hepatitis B is the same as for the treatment of HIV: 300 mg once daily. Dosage adjustment is recommended for patients with renal impairment.
For further information, see